MetaCap

Avalo Therapeutics (AVTX) vs CorMedix (CRMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CorMedix (CRMD) has outperformed Avalo Therapeutics (AVTX) over the past year, losing 45.6% versus a loss of 62.1%. Over five years, CRMD leads with a +3.9% price change compared with -99.9% for AVTX. CorMedix is the larger company by market cap ($419.2 million vs $390.9 million), about 1.1 times the size.

CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -132642.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVTX-62.09%CRMD-45.56%
+36%-16%-68%
Nov 21, 20251 yearNov 20, 2026
AVTX-99.89%CRMD+2.73%
+204%+45%-114%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVTX versus CRMD key metrics
MetricAVTXCRMD
Share price$6.76$5.27
Market cap$390.88M$419.16M
1-day change+0.15%+3.74%
YTD return-62.78%-54.69%
1-year return-62.09%-45.56%
5-year return-99.89%+3.94%
P/E ratio (TTM)—8.23
Forward P/E—15.06
EPS (TTM)$-2.26$0.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$59.00K$311.71M
Revenue growth (YoY)-86.62%+617.03%
Net income (latest FY)$-78.26M$163.06M
Gross margin—88.46%
Operating margin-123601.69%48.17%
Net margin-132642.37%52.31%
52-week high$24.27$13.02
52-week low$6.53$4.47
Distance from 52-week high-72.15%-59.52%
Analyst consensusstrong_buybuy
Avg. price target upside+414.79%+161.86%
Average volume1.80M1.44M
Shares outstanding57.82M79.54M
Employees33191
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRMD has outperformed AVTX by 16.5 percentage points over the past year.
  • CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
  • CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -86.62%).

About Avalo Therapeutics

AVTX stock →

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About CorMedix

CRMD stock →

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees

AVTX vs CRMD FAQ

Which is bigger, Avalo Therapeutics or CorMedix?

CorMedix (CRMD) is larger, with a market capitalization of $419.16M compared with $390.88M for Avalo Therapeutics (AVTX).

Which stock has performed better over the past year, AVTX or CRMD?

CRMD returned -45.56% over the past 12 months, compared with -62.09% for AVTX (price return, excluding dividends). Past performance does not predict future results.

Are Avalo Therapeutics and CorMedix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons